Genmab A/S (CPH: GEN) announced on Monday the appointment of Marisol Peron as corporate vice president, Communications and Investor Relations, effective 11 March 2019.

In her new role, Peron will be responsible for the strategic management of both internal and external communications and investor relations efforts for Genmab.

The company said Peron replaces Rachel Curtis Gravesen, who will pursue new opportunities elsewhere, but will be available during a short transition period.

Peron joins Genmab with over 20 years' experience in corporate communications in the life sciences industry. Most recently, Peron served as the VP of Communications for North America at Ipsen Biopharmaceuticals. Prior to that, she spent 17 years at Sanofi, where she led communications for the vaccines division in North America and held various communications roles for Sanofi's oncology, cardiovascular and diabetes business units.

Also, Andrew Carlsen, who recently joined the company as senior director Investor Relations, continues to be the contact point for investors and analysts.

Genmab is an international biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer.